MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ
4.970
+0.150
+3.11%
Closed 16:00 10/04 EDT
OPEN
4.900
PREV CLOSE
4.820
HIGH
5.26
LOW
4.680
VOLUME
94.44K
TURNOVER
260.57K
52 WEEK HIGH
6.25
52 WEEK LOW
2.300
MARKET CAP
152.39M
P/E (TTM)
-10.6106
1D
5D
1M
3M
1Y
5Y
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Benzinga · 09/19 05:53
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 09/16 18:06
Anixa Biosciences' Ovarian Cancer CAR-T Therapy To Be Presented At The Rivkin Center & American Association Of Cancer Research 14th Biennial Ovarian Cancer Research Symposium
Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose
Benzinga · 09/12 12:32
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of th...
PR Newswire · 09/12 12:30
BRIEF-Anixa Biosciences Inc Files For Mixed Shelf Of Up To $200 Mln
BRIEF-Anixa Biosciences Inc Files For Mixed Shelf Of Up To $200 Mln
Reuters · 09/09 21:48
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/15 22:58
Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX<...
Seekingalpha · 08/15 16:19
Anixa Initiates Patient Dosing in Initial-Stage Ovarian Cancer Study
Anixa Biosciences (NASDAQ: ANIX) commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Benzinga · 08/15 13:47
More
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on oncology and infectious disease. The Company is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. It is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its CAR-T technology can be used as a treatment against multiple solid tumor types. The Company’s segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics activities, and Patent Licensing activities. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.